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Abstract Systemic lupus erythematosus (SLE) is an autoim-
mune rheumatic disease with a prevalence of approximately 1
in 1000. Over the last 30 years, advances in treatment such as
use of corticosteroids and immunosuppressants have im-
proved life expectancy and quality of life for patients with
lupus and the key unmet needs have therefore changed.
With the reduced mortality from disease activity, development
of cardiovascular disease (CVD) has become an increasingly
important cause of death in patients with SLE. The increased
CVD risk in these patients is partly, but not fully explained by
standard risk factors, and abnormalities in the immune re-
sponse to lipidsmay play a role. Invariant natural killer Tcells,
which are triggered specifically by lipid antigens, may protect
against progression of subclinical atherosclerosis. However,
currently our recommendation is that clinicians should focus
on optimal management of standard CVD risk factors such as
smoking, blood pressure and lipid levels. Fatigue is one of the
most common and most limiting symptoms suffered by pa-
tients with SLE. The cause of fatigue is multifactorial and
disease act ivi ty does not explain this symptom.
Consequently, therapies directed towards reducing inflamma-
tion and disease activity do not reliably reduce fatigue and
new approaches are needed. Currently, we recommend asking
about sleep pattern, optimising pain relief and excluding other
causes of fatigue such as anaemia and metabolic disturbances.
For the subgroup of patients whose disease activity is not fully
controlled by standard treatment regimes, a range of different
biologic agents have been proposed and subjected to clinical
trials. Many of these trials have given disappointing results,
though belimumab, which targets B lymphocytes, did meet its
primary endpoint. New biologics targeting B cells, T cells or
cytokines (especially interferon) are still going through trials
raising the hope that novel therapies for patients with refrac-
tory SLE may be available soon.
Keywords Systemic lupus erythematosus . Cardiovascular
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune rheu-
matic disease that affects women nine times more commonly
than men and typically presents between the ages of 20 and
40. In the UK, it has an incidence of 4.91 per 100,000 per year
and a prevalence of 97 per 100,000 [1]. There are two different
sets of classification criteria for SLE: the American College of
Rheumatology (ACR) criteria [2] and the Systemic Lupus
International Collaborative Clinics criteria [3]. The SLICC
criteria are slightly less specific and more sensitive than the
ACR criteria but both recognise the principles that SLE is
characterised by the presence of autoantibodies and can cause
clinical effects in multiple different organs or tissues.
Mortality from SLE has improved dramatically over the
last 50 years from a 5-year survival of 50% in the 1950s [4]
to 95% now [5]. This improvement was primarily brought
about by the introduction of treatment with corticosteroids
and immunosuppression, first with cyclophosphamide [6]
and azathioprine and later with mycophenolate [7]. As a re-
sult, there are fewer deaths from active lupus and a higher
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proportion of deaths occur from comorbidities such as cardio-
vascular disease and infection [8].
In parallel with these improvements, the major unmet
needs for patients with lupus have changed over time. Thus,
as these patients live longer, the development of premature
cardiovascular disease has become an important issue.
Symptom control remains important and fatigue is one of
the most common, limiting and difficult-to-treat symptoms
in patients with SLE. Finally, an important subgroup of pa-
tients with SLE is refractory to treatment with standard re-
gimes of corticosteroids and immunosuppressants.
Considerable effort has been directed towards development
of new biologic agents for this refractory subgroup. In this
review, we will concentrate on three major unmet needs in
the management of patients with SLE, as follows:
1) Management of cardiovascular disease risk in patients
with SLE
2) Management of fatigue in patients with SLE
3) Management of refractory SLE.
Cardiovascular Disease in SLE
Evidence for Increased Risk of CVD in SLE
Patients with SLE are at an increased risk of developing isch-
aemic heart disease or stroke—together termed cardiovascular
disease (CVD)—compared to healthy people of the same age
and gender. A large multinational study of 9547 patients with
SLE [8] recorded 1255 deaths and 313 of these were due to
CVD. The presence of SLE in women between the ages of 35
and 44 increases the risk of developing coronary disease by
50-fold, though across all ages the increased risk is less, at
seven–tenfold [9].
As well as established CVD, it has also been shown in a
number of different studies using a variety of imaging tech-
niques (such as vascular ultrasound and electron beam tomog-
raphy) that lupus patients also have a considerably higher
prevalence of asymptomatic atherosclerotic plaque compared
to healthy controls [10, 11].
Whilst traditional CVD risk factors may well account for
some of this increased risk, they fail to explain all of it. Studies
have shown that traditional CVD risk calculators based on the
Framingham risk equations underestimate CVD risk in lupus
[12, 13]. After adjusting for Framingham risk factors, it has
been reported that patients still have a seven–tenfold increased
risk of CVD [14].
To explain this unattributed risk, several authors have pos-
tulated that the immune dysfunction that characterises SLE
may also promote development of atherosclerosis, leading to
CVD [15]. It has been difficult to obtain clear proof that
specific immunological factors can do this, but if such mech-
anisms can be identified, it could help in the development of
biomarkers to predict CVD risk in patients with SLE and also
in designing immunomodulatory therapies to reduce this risk.
Possible Immunological Mechanisms Linking Lipids
and CVD in SLE
Inflammation and lipid dysfunction are central to the patho-
genesis of atherosclerosis. Inflammation plays a role in both
atherosclerotic plaque formation and plaque rupture that oc-
curs during an acute event [16].
SLE is characterised by lipid defects and chronic inflam-
mation. Links between lipids and the pathogenesis of athero-
sclerosis in SLE are not fully understood and are likely to be
multifactorial. Possible mechanisms include:
& Immune complex deposition which may stimulate the ac-
cumulation of cholesterol in atherosclerotic plaques [17].
& Dysfunctional pro-inflammatory high-density lipoprotein
(HDL) cholesterol commonly present among SLE patients
may accelerate low-density lipoprotein oxidation and ath-
erosclerosis [18].
& Apolipoprotein A1 (ApoA1) is the main constituent of
HDL. Anti-HDL and/or anti-apoA1 antibodies could in-
terfere with the protective functions of HDL and could
thus promote development of CVD. Anti-apoA1 antibod-
ies have been associated with acute coronary syndromes
in the general population [19] and patients with rheuma-
toid arthritis [20].
Anti-apoA1—a Possible Link Between Disease Activity
and Development of Atherosclerosis in Patients with SLE
Anti-apoA1 antibodies are potentially relevant to pathogene-
sis of CVD in patients with SLE. Anti-HDL and/or anti-
apoA1 antibodies could interfere with the protective functions
of HDL and could thus promote development of CVD. The
presence of anti-apoA1 and/or anti-HDL is associated with
reduced activity of the antioxidant enzyme paraoxonase in
SLE. This could cause increased oxidation of low-density
LDL, which is a risk factor for the development of atheroma
[21]. O’Neill et al. studied levels of anti-HDL, anti-apoA1 and
anti-C-reactive protein (anti-CRP) in patients with SLE clas-
sified according to disease activity [22]. Raised anti-apoA1
levels were clearly associated with both current and persistent
disease activity in both prospective and retrospective analyses
and in longitudinal and cross-sectional studies [22]. However,
in a subsequent study, the same group did not find any statis-
tically significant association between levels of IgG anti-
apoA1 and the development of atherosclerosis in patients with
SLE [23].
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Invariant Natural Killer Cells (iNKT Cells)
Invariant natural killer T cells (iNKT) are a small population
of specialised immune cells that constitute less than 0.1% of
peripheral blood mononuclear cells. They are thought to be
important in a broad range of immune responses and are
unique in that they respond to lipid antigens presented by
the CD1d molecule on antigen presenting cells [24].
iNKTcells could potentially play a role in both autoimmunity
and atherosclerosis. iNKT cells are reduced in number and have
impaired function in SLE suggesting a protective role in autoim-
munity [25]. Work from mouse models suggests a potential pro-
atherogenic function of iNKTcells [26]; however, human studies
have suggested that iNKTcells may have a protective role in the
early stages of atherosclerosis by promoting atherosclerosis res-
olution via increased IL-10 production [27].
Smith et al. at University College London investigated the
role of iNKTcells in the development of subclinical atheroscle-
rosis in 100 patients with SLE who had no previous history of
CVD, using vascular ultrasound to quantify the presence of
plaque and its composition [28]. In this SLE patient cohort,
36% had subclinical plaque, supporting previous studies [11].
SLE patients with pre-clinical plaque (SLE-P) had a distinct
anti-inflammatory iNKT cell profile characterised by increased
activation and IL-4 production, which correlated with serum
lipid expression levels and altered lipoprotein composition.
iNKT cells differentiated in the presence of serum from SLE-
P patients induced the polarisation of M2-like macrophages
(anti-inflammatory) in vitro. This protective iNKT cell pheno-
type was lost in SLE patients who had a cardiovascular event.
These SLE-CVD patients had a different iNKTcell phenotype,
characterised by low peripheral blood frequency, increased
CD8+ phenotype and a low expression of IL-4 and IFN-ɣ com-
pared to SLE-P and SLE-NP patients. This was associated with
increased expression of pro-inflammatory monocytes (CD14
and CD16+) and reduced M2-like monocyte frequency. The
results support an athero-protective role for iNKT cells driven
by serum lipids during the early stages of atherosclerosis, which
was lost or overwhelmed during the development of clinical
atherosclerosis [28].
Smith et al. [28] also tested to see whether dyslipidaemia, a
risk factor for atherosclerosis, was associated with the altered
iNKT cell activation in SLE-P patients. Serum lipid composi-
tion analysed using proton nuclear magnetic resonance spec-
troscopy revealed elevated concentrations of VLDL but not
LDL or HDL particles in SLE-P compared to SLE-NP patients.
The proportions of free cholesterol, cholesterol esters, phospho-
lipids and triglycerides carried by lipoprotein subclasses (par-
ticularly in VLDL lipoproteins) as well as other serum
metabolomic components were significantly different in SLE-
P compared to SLE-NP patients. In comparison, serum lipid
measures quantified in the clinical laboratory as part of routine
patient management were within normal clinical ranges [28].
In conclusion, the results published suggest that iNKTcells
may have a unique phenotype during different stages of ath-
erosclerosis and that this may be driven by dyslipidaemias.
It may well be that the traditional targets such as LDL cho-
lesterol targeted by statins are in fact not the correct lipids that
should be targeted in lupus and that other serum lipids such as
VLDL may be more relevant for patients with SLE [29].
How Should We Manage CVD Risk in SLE?
In the future, identification of immunological factors may en-
able us to identify a subgroup of patients who are at a higher
risk of CVD to enable risk stratification and more stringent
control of disease activity and traditional CVD risk factors.
At present, however, management of traditional risk factors
is the best strategy for modifying CVD risk. SLE subjects
should be screened annually for cardiac risk factors—one re-
port showed that only 26% of patients had four cardiac risk
factors assessed annually [30]. In the Systemic Lupus
International Collaborative Clinics cohort, hypercholesterol-
emia was not treated in up to two thirds of patients [30].
Management of CVD risk can be undertaken by a target-
based approach. As SLE is a very high risk condition for
CVD, some experts have suggested that it can be viewed as
a Bcoronary heart disease equivalent^ like diabetes and there-
fore targets for hypertension and raised cholesterol should be
adjusted accordingly [31]. Table 1 outlines a possible scheme
for targeting these risk factors in patients with SLE.
Anti-malarials are commonly used in SLE and have been
found to have cardioprotective properties with decreased prev-
alence of carotid plaque [32] reduced vascular stiffness [33]
and cholesterol lowering effects on patients in patients on
cor t icos tero ids . In a nes ted case-cont ro l s tudy,
hydroxychloroquine demonstrated a risk reduction of 68%
for all thromboembolic events [34].
Mycophenolate mofetil has shown favourable results in
mouse models with atherosclerosis [35]. In non-SLE patients,
short courses of mycophenolate have shown decreased T cell
activation in carotid plaques. Although studies in SLE patients
are yet to show favourable outcomes [36], larger studies are
required.
Potential novel therapies include pathways involved in ath-
erosclerosis and endothelial dysfunction. Type 1 interferons
are an example of such mediators and could potentially be
targeted to reduce CVD risk in SLE (see section on refractory
SLE below).
Fatigue in Systemic Lupus Erythematosus
The majority of patients with lupus often report fatigue to be
the single most troublesome symptom of their illness that neg-
atively impacts on their quality of life [37] Between 80 and
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90% of patients with lupus report fatigue to be the most de-
bilitating symptom of their disease [38, 39]. Interestingly, pa-
tients with both clinically and serologically well-controlled
lupus continue to demonstrate marked levels of fatigue, in
spite of apparent disease remission [40–42]. This troublesome
symptom has wide ranging effects on quality of life, resulting
in significant disruption to daily function [43]. This has wider
implications for work, exercise, and leisure activities with a
high prevalence of employment disability reported [44].
Furthermore, fatigue is associated with impaired concentra-
tion, which often has implications on education, in particular
in younger patients with lupus.
Metabolic Disorders
In some cases, an obvious cause for fatigue is easily identifi-
able: for example, intercurrent metabolic disorders, such as
hypothyroidism, which should be screened for. In addition,
anaemia is the most common haematological manifestation
of lupus and can frequently contribute to fatigue [45]. The
most common forms of anaemia in lupus are anaemia of
chronic disease, iron deficiency anaemia and autoimmune
haemolytic anaemia [45]. However, in the vast majority of
cases, an identifiable cause for fatigue is not obviously detect-
able. A variety of factors have been proposed to play a role in
the development of fatigue in lupus, although there is no
widely accepted unifying mechanism described. It is likely
that the aetiology of fatigue in lupus is multifactorial.
Sleep Disturbance
One important factor to consider when assessing patients with
high levels of fatigue is the role of sleep disturbance. This can
include difficulty initiating sleep, maintaining sleep and early
morning wakening. Problems with sleep have been widely
reported in a number of autoimmune rheumatic conditions
[46–48]. In a study of 81 female patients with lupus,
Palagini et al. reported insomnia and poor sleep quality was
common. Nearly two thirds of patients described poor sleep
quality and/or early morning awakening (of which one third
also reported insomnia) [49]. A key predictor of poor sleep
quality in patients with lupus is pain [50]. It has been previ-
ously found that fatigue is closely associated with patient pain
scores [51]. In a study by Gudbjornsson and Hetta, patients
with lupus were found to report more pain when trying to fall
asleep and during the night when compared with healthy con-
trols [52]. Joint pain from arthralgia and arthritis is commonly
seen in lupus and this can cause significant sleep disruption.
Fibromyalgia, a condition that commonly co-exists with lu-
pus, is another important factor to consider as this can result in
nocturnal pain contributing to sleep disruption and fatigue [53,
54]. Other factors that lead to sleep disruption in lupus patients
Table 1 Possible scheme for assessment of traditional CVD risk factors in SLE
Risk
factor
Prevalence in SLE Frequency of assessment Target and treatment options
Smoking 17–21% of patients with SLE smoke Annually Stop smoking (in all patients)
Referral to cessation clinics, specialist nurse,
drug treatments e.g. nicotine replacement therapy
Cholesterol Hypercholesterolemia 34–51%
Typically low HDL and raised
triglycerides (from inflammatory
disease ± steroids)
Annual fasting lipids namely total,
HDL, LDL, and triglycerides
Adult Treatment Panel 111 guidelines [22]—LDL cholesterol
key lipid parameter:
1. LDL cholesterol < 2.6 mmol/l no action review annually
2. LDL 2.6–3.4 mmol/l therapeutic lifestyle changes- diet
and weight reduction
3. LDL > 3.4 mmol/l or still > 2.6 despite lifestyle
modification— drug therapy, e.g. statin
Body mass
index
Frequently seen in truncal distribution
in SLE
Annually >25 kg/m2 (over weight):
Consider steroid dose adjustment, lifestyle modification, exercise
programmes, dietary education, reducing alcohol.
Monitor over set period of time.
If above fail, then drug treatment as recommended by NICE [22]
Diabetes
mellitus
5–7% Screening at every visit as part of
SLE assessment with a urine
sample
Random glucose—annually at least
Monitor those on high dose steroids
more closely
DM diagnosed in presence of fasting glucose ≥ 7 mmol/l or
random blood glucose or ≥ 11 mmol/l
Referral to specialist in diabetes for all patients with diabetes.
Blood
pressure
Common in SLE At every clinic visit and at least
annually
1. Ideal target < 130/80 mmHg
2. > 140/90 review closely and lifestyle measures offered. Steroid
treatment reviewed and renal function monitored
3. If > 140/90 despite measures in two-drug treatment based on
age and comorbidities. Start ACE inhibitors in all with renal
lupus
4. Review BP every 3 months after starting treatment and ideally
be kept < 130/80
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include respiratory symptoms and restless leg syndrome [55,
56]. Intercurrent depression and anxiety can also negatively
impact on sleep. Da Costa et al. reported that in a sample of
100 womenwith lupus, depressedmood and a lack of physical
activity significantly contributed to poor sleep quality [57].
The impact of sleep disturbance leads to significant reduction
in physical activity, which has a variety of negative effects on
psychological well-being [58]. A number of studies have
highlighted high levels of depression and anxiety in patients
with lupus [59, 60]. The presence of these mental health prob-
lems is commonly associated with fatigue in lupus patients
[38, 47]. Physical deconditioning is believed to also play a
role in fatigue in lupus. Various studies have reported that
patients with lupus have a lower cardiovascular capacity and
reduced muscle strength when compared with the healthy
population [38, 61, 62].
Medication
Another important consideration in the development of fa-
tigue in patients with lupus is the role of medication.
Corticosteroids are well known to cause sleep disturbance that
can cause or exacerbate fatigue [63]. A study by Jump et al.
interestingly noted that patients taking non-steroidal anti-in-
flammatory drugs (NSAIDs) were found to have higher levels
of fatigue when compared with those who did not [64].
However, this was noted to be no longer significant when
controlled for pain scores [64]. In addition, opiate-based anal-
gesia, anti-depressants and anxiolytics can commonly have
sedating side effects, which can exacerbate fatigue [65].
Central Nervous System Involvement in Lupus
Lupus is known to cause significant and sometimes severe
neurological involvement resulting in a number of diverse
symptoms [66]. The various neurological and psychiatric
manifestations that occur in lupus pose both diagnostic and
therapeutic challenges. Lupus patients with central nervous
system (CNS) involvement have been reported to have signif-
icant reduction in quality of life outcomemeasures when com-
pared with those who have other serious manifestations of the
disease (for example, renal involvement). Furthermore, pa-
tients with CNS involvement had significantly higher fatigue
scores when compared with those who did not have CNS
involvement (based on the SF-36 questionnaire) [67].
In some cases, in spite of no obvious cause and in the
absence of apparently obvious disease activity, patients con-
tinue to report high levels of fatigue. A number of suggestions
have beenmade including the possibility of subclinical central
nervous system involvement, which may lead to fatigue. One
possible explanation is that disruption and dysregulation with-
in the blood-brain barrier (BBB) leaves the central nervous
system open to the deleterious effects of infiltrating pro-
inflammatory cytokines. This hypothesis is difficult to test
due to obvious difficulties in monitoring CNS cytokines with-
out invasive tests. In a recent study by Gulati et al., diffusion-
weighted magnetic resonance imaging (MRI) was used to
measure regional BBB integrity in patients with juvenile-
onset lupus. It was noted that patients with lupus demonstrated
increased regional capillary permeability within the BBB
when compared with healthy controls [68]. How this relates
to fatigue is yet to be fully established however.
In addition to disruption of the BBB, diffusion-weighted
MRI has been used to assess for evidence of cortical damage
in lupus. Wiseman et al. recently reported an increased pres-
ence of microstructural white matter damage in patients with
lupus when compared with healthy controls of the same age
[69]. However, in this study, there was no clear association
between the prevalence of these white matter changes and the
levels of fatigue seen. Interestingly, the study did note that
lupus patients with poorer cognitive function had higher cir-
culating levels of interleukin-6 (IL-6). The way in which IL-6
may result in the white matter changes and cognitive function
is however not understood [69].
Pro-inflammatory Cytokines and Potential Biomarkers
for Fatigue
As mentioned, fatigue remains a troublesome symptom in
patients with lupus who appear to have both clinically and
serologically well-controlled disease [40]. Furthermore,
there is no convincing evidence that fatigue levels are
related to lupus disease activity [41]. In view of this, there
has been an increased focus of late to identify surrogate
biomarkers of fatigue in lupus. A number of serum
markers have been investigated by means of investigating
the potential pathogenesis and treatment of fatigue in lu-
pus. Omdal et al. have focused on pro-inflammatory se-
rum cytokines including TNF-α, IL-2, IL-6, IL-10,
TGFβ- and interferon-α. However, there was no demon-
strated correlation between serum concentrations of these
circulating cytokines and levels of fatigue [41]. In addi-
tion, antiphospholipid antibodies (present in 30–40% of
lupus patients [70]) were also measured, although similar-
ly there was no significant association with fatigue in this
case.
Abnormal oxidative metabolism and mitochondrial dys-
function have been proposed as possible mechanisms for fa-
tigue in lupus. Reactive oxygen species (ROS) are produced
as a result of normal aerobic mechanism. The clearance of
these potentially damaging ROS is well maintained by several
enzyme systems. Prolonged exposure to ROS is believed to
result in oxidative damage to DNA [71] and is believed to
have a role in the pathogenesis of lupus [72–74]. Segal et al.
found that plasma levels of F2-isoprostane (a marker of oxi-
dative stress) were increased in lupus patients with low disease
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activity when compared with healthy controls. Interestingly,
levels of F2-isoprostane were a predictor for high fatigue
scores measured by Fatigue Severity Scale (FSS). It was pro-
posed that this may be a useful biomarker of mitochondrial
function in lupus patients with high levels of fatigue [75].
Treatment of Fatigue in Patients with SLE
As has already been outlined, there is no reliable treatment for
fatigue in patients with lupus. Fatigue and quality of life out-
comes are often measured in clinical trials in lupus. The
BLISS trial investigated the use of belimumab (a B lympho-
cyte stimulator-specific inhibitor) in lupus. This trial reported
an improvement in fatigue (measured by FACIT Fatigue
score) as a secondary outcome [76].
Vitamin D deficiency is a common finding in both the
general population and in patients with lupus [77, 78].
Previously, low level of vitamin D (25-hydroxyvitamin D3)
has been found to correlate with increased lupus disease ac-
tivity (although did not correlate with complement levels or
damage scores) [79]. A recent randomised, double-blind pla-
cebo-controlled trial of weekly high dose (50,000 I/U) oral
vitamin D supplementation in patients with juvenile-onset lu-
pus was noted to show a significant improvement in terms of
both disease activity (measured by SLEDAI) and fatigue
levels (measured by the Kids Fatigue Severity Scale), which
suggests that the treatment of low vitamin D levels may be
useful in the management of patients with lupus [80].
Non-pharmacological treatment of fatigue in lupus has pre-
viously been investigated by Tench et al., in a trial that com-
pared graded exercise, relaxation therapy and no intervention
[81]. The exercise group was asked to complete three 30–
50 min exercise sessions a week for a period of 12 weeks.
Exercise predominantly included walking, cycling and swim-
ming. By comparison, the group assigned to relaxation thera-
py was asked to listen to a 30-min relaxation tape three times a
week. The final group was asked to continue with their usual
daily routines. Fatigue levels were noted to significantly im-
prove in the patient group undergoing graded exercise when
compared with the other two groups at 12 weeks. However,
these improvements were not maintained at 3-month follow-
up. This was believed to be due to the fact that not all patients
continued with the regular exercise regime [81].
Overall, recommendations for management of fatigue in
patients with SLE are summarised in Table 2.
In conclusion, fatigue is a prevalent problem faced by
many patients with lupus. This is often independent of disease
activity and remains problematic even in those with well-
controlled disease. Escalation of standard immunosuppressive
therapy is often ineffective in the treatment of fatigue. The
causes of fatigue in lupus are poorly understood and likely
to be multifactorial.
Treatment of Refractory Lupus
This part of the review will focus on the pharmacological
aspect of managing SLE patients who do not respond to con-
ventional treatment such as current immunosuppressants and
steroids.
Steroids and Current Immunosuppressive Treatments
The use of corticosteroids revolutionised the treatment of SLE in
the 1950s and still remains as themainstay of treatment (Table 3).
Nonetheless, they are not exempt from short-term and long-term
side effects, which are major issues in SLE management. The
risk of damage is higher with high doses albeit there is no safe
dose for chronic use. It is well known that even small doses taken
for a long period of time will increase the morbidity. In fact, there
are studies which have shown that the hazard ratio for organ
damage increases dramatically with prednisone doses of 6 to
12 mg/day, after adjusting for confounding factors by indication
due to SLE disease activity [82]. In addition, development of
osteopenia and osteoporosis is an important potential adverse
effect of taking corticosteroids for long periods. Every attempt
should be made to minimise the dose and duration of corticoste-
roid exposure [83].
Initially, cyclophosphamide was considered the standard of
care in those patients with refractory lupus, particularly those
with lupus nephritis. Nevertheless, it was associated with sig-
nificant side effects including infections, malignancy and in-
fertility. Therefore, lower doses of cyclophosphamide and/or
replacement by mycophenolate became effective options for
induction therapy and likewise, better safety treatments [84,
85]. Ethnicity seems to be important in the responses to these
treatments. Previous studies have demonstrated that Afro-
Caribbean patients have better response to mycophenolate
than Caucasian and Asian patients [86].
Azathioprine and mycophenolate have been demonstrated
to be effective options for maintenance therapy in randomised
trials. In the ALMS trial, mycophenolate was superior to aza-
thioprine [87]; however, this did not remain true in the
MAINTAIN trial [88].
Table 2 Recommendations for the management of fatigue in lupus
1. Enquire about sleep disturbance (this usually has a bidirectional role
in fatigue)
2. Address regular medication and reduce steroids to the minimal
effective dose
3. Ensure adequate pain control
4. Screen for other exacerbating syndromes (such as fibromyalgia,
depression and anxiety)
5. Identify any coexisting metabolic disorders (such as anaemia,
hypothyroidism and vitamin D deficiency)
6. Encourage regular paced activity
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Despite the dramatic improvements in the management
of SLE brought about by use of these drugs, there are still
many patients who fail to respond to those treatments.
Novel approaches have been tried in order to assess these
issues. For instance, calcineurin inhibitors such as
ciclosporin and tacrolimus have shown hopeful results in
SLE patients who did not respond to first-line therapies
[89]. Therefore, it is imperative to develop large con-
trolled clinical trials in order to confirm these prior
findings.
Table 3 Current and future treatments for SLE
Main indications Potential risks (most common—but not
an exhaustive list)
Current treatments for SLE
Corticosteroids • Acute flares of the disease
• To maintain remission in patients with previous severe
forms of lupus(e.g. renal/cerebral)
• Increased cardiovascular risk
• Osteoporosis- Increased risk of
fragility fractures
• Cataracts
• Avascular necrosis
Hydroxychloroquine chloroquine • Mild SLE and SLE with organ involvement in
combination with other immunosuppressants
• In general, anti-malarials should be considered in every
patient with SLE unless there are contra-indications
• Retinal toxicity
• Gastrointestinal side effects
Azathioprine • Maintenance therapy in cases with major organ
involvement usually in combination with corticosteroids
• Steroid-sparing agent in some cases
• Gastrointestinal side effects
• Bone marrow toxicity
(dose-dependent)
• Infections
• Hepatotoxicity
Mycophenolate mofetil • Lupus nephritis (induction and maintenance therapy)
• Same indications as azathioprine
• Gastrointestinal side effects
• Bone marrow aplasia (very unlikely)
• Opportunistic infections
• Contra-indicated in pregnancy
Cyclophosphamide (usually intravenous—the
low dose Eurolupus regime is often used)
• Lupus nephritis
• CNS involvement—vasculitis
• Alveolar haemorrhage
• Haemorrhagic cystitis
• Bone marrow suppression
• Opportunistic infections
• Increased risk of cancer
• Infertility
Methotrexate • Joint involvement
• Skin involvement
• Steroid sparing agent in some cases
• Bone marrow suppression
• Hepatotoxicity
• Lung toxicity-lung fibrosis
Belimumab • Skin involvement
• Joint involvement
• Limited evidence in major organ involvement
• Elevated anti-dsDNA, low complement
• Increased risk of infections
• Infusion reaction
Rituximab • Lupus nephritis
• Refractory thrombocytopenia or haemolytic anaemia
• CNS involvement (case-report series)
• Increased risk of infections
• Bone marrow suppression
• Multifocal leukoencephalopathy
• Infusion reaction
Future treatments for SLE
Abatacept • Lupus arthritis • Increased risk of infections
Ongoing clinical trial phase III
Fostamatinib (R788) • Lupus nephritis • Preliminary results in murine models
• No data in humans
Laquinimod/paquinimod • Lupus arthritis
• Lupus nephritis
• Arthralgia
• Myalgia
• Pharyngolaryngeal pain
• Dose-dependent side effects
Forigerimod (Lupuzor) • Moderate active SLE • Ongoing phase III trial
Sirukumab • Skin disease
• Mild SLE
• Reduction in white cell, neutrophil and
platelet counts (dose-independent)
Sifalimumab • Moderate active SLE • Herpes zoster infections
Anifrolumab • Moderate active SLE • Ongoing phase III trial
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Biologic Therapy for SLE
Over the past decade, there has been a significant develop-
ment in biologic therapies for SLE patients. These therapies
can be divided into those directed at B cells and non-B cell
targets. Moreover, T cell interactions or cytokines such as type
I interferons are also emerging targets with pivotal roles in
SLE pathogenesis.
B cells as a Target for Treatment in SLE
Rituximab
B cells play a central role in the pathogenesis of lupus.
Polyclonal B cell activation results in the production of auto-
antibodies directed against many nuclear, cytoplasmic and
plasma membrane antigens. Almost 95% of patients with
SLE have anti-nuclear antibodies (ANA).Many of the clinical
manifestations of lupus are a result of immune complex depo-
sition in tissues and subsequent multi-organ damage. Immune
complexes are formed as anti-nuclear antibodies bind to nu-
clear material. B cells also perpetuate the inflammatory re-
sponse by presenting auto-antigens to T cells and producing
pro-inflammatory cytokines [90].
Rituximab, a chimeric anti-CD20 antibody, efficiently and
reliably depletes CD20-positive B cells. Two large phase III
randomised controlled trials involving patients with moderate
to severe lupus but non-renal SLE (EXPLORER) [91] and
lupus nephritis class III or IV (LUNAR) [92] have evaluated
rituximab for treatment of SLE, although both failed to meet
their primary endpoints of significant reduction of disease
activity compared to placebo. In the EXPLORER trial, the
group treated with rituximab had significant improvements
in serology-reduced anti-dsDNA antibody (p = 0.006), in-
creased C3 (p = 0.0029) and C4 levels (p = 0.0045)—at the
termination of the trial, although there were no significant
clinical improvements [91]. In the LUNAR trial, there was a
trend to an improved response rate in Afro-Caribbean subjects
treated with rituximab. A statistically significant serological
improvement in the treatment group was found with anti-
dsDNA antibodies falling (p = 0.007) and C3 levels rising
(p = 0.03) [92].
A prospective observational study of rituximab [93] as part
of corticosteroid-sparing regimen in lupus nephritis patients
showed promising results with good renal outcomes in 45/50
patients treated on an open-label basis. This led to a
multicentre randomised controlled trial (RITUXILUP) with
rituximab as induction therapy followed by maintenance my-
cophenolate mofetil. However, that trial was recently halted
due to difficulties with recruitment. The RING study
(Rituximab for lupus Nephritis with Remission as a Goal) is
another ongoing trial of rituximab which is an open-label,
multicentre trial aiming to determine the efficacy of rituximab
in achieving complete renal remission in lupus nephritis pa-
tients with persistent proteinuria. Patients who have been
treated for a minimum of 6 months of standard immunosup-
pression may participate in the trial [ClinicalTrials.gov
identifier:NCT01673295].
Belimumab Belimumab is a fully humanised monoclonal an-
tibody that binds to soluble human B lymphocyte stimulator
(BLyS) and was the first new drug for SLE approved by the
US authorities in 50 years. It has been studied in two large
randomised controlled trials in SLE (BLISS-52 [n = 865] [76]
and BLISS-76 [n = 819] [94]). These trials were performed in
patients with active disease (defined by a SLE Disease
Activity Score Index of ≥ 6) and the majority of patients en-
tered with active arthritis and/or a rash. Patients were
randomised to receive placebo plus or intravenous infusions
of belimumab at 1 or 10 mg/kg at 2 and 4 weeks, and then
every month until 48 weeks. Both of these studies excluded
SLE patients with active lupus nephritis or neuropsychiatric
disease. This exclusion is commonly seen in lupus trials and is
important as those manifestations are often seen in patients
with refractory SLE.
The belimumab studies, unlike those with rituximab, met
their primary endpoints, with significantly greater response
rates in the treatment groups than the placebo groups.
Belimumab was more effective in SLE patients who were
serologically active, that is those who were anti-dsDNA anti-
body positive and were hypocomplementemic [95]. The
BLISS-LN phase III study has been devised to evaluate the
efficacy and safety of belimumab plus standard of care in
act ive lupus nephrit is , and is recrui t ing patients
[ClinicalTrials.gov identifier:NCT01639339].
Epratuzumab
Epratuzumab is a monoclonal antibody targeting CD22 recep-
tors (a cell surface marker on transitional B cells and naïve
mature B cells) leading to moderate B cell depletion via
antibody-dependent cellular cytotoxicity (ADCC). There have
been three different randomised controlled trials in moderate-
to-severe active SLE. A phase II study (EMBLEM)was prom-
ising as a dose of 2400 mg per month in divided doses was
safe and appeared to show improved efficacy compared to
placebo [96]. However, two phase III studies failed to meet
their primary endpoint and did not show benefit of
epratuzumab over placebo plus standard therapy [97].
Atacicept
Atacicept is a recombinant human fusion protein that targets
the BlyS/APRIL axis. There have been three phase II/III stud-
ies. One of these randomised 461 patients to placebo or two
different doses of atacicept. The outcome measure was the
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ability to prevent flares of lupus in patients whose disease was
inactive at the start of the trial period. As with other B cell
targeting agents, atacicept led to an improvement in serology
(anti-dsDNA and complement) but response was only better
than placebo in the higher dose group. The trial in this higher
dose group was halted due to two fatal infections [98].
T cells as a Target for Treatment in SLE
T lymphocytes play a fundamental role in SLE. They enhance
autoantibody production by B cells and are believed to trigger
SLE disease. On the other hand, T cells themselves can only
be stimulated by interaction with specialised antigen present-
ing cells (APCs), which include B cells. In an APC-T cell
interaction, there are two points of contact between the cells.
Firstly, the APC presents the antigen to the T cell in associa-
tion with a major histocompatibility complex (MHC) mole-
cule; this is the antigen-dependent interaction. Secondly, there
is a co-stimulatory signal between pairs of ligands, one on the
APC and one on the T cell, leading to the antigen-independent
interaction [99].
Many drugs, which act as inhibitors of T cell/APC co-stim-
ulation, have failed in different clinical trials. Some examples
are anti-CD40L treatment such as IDEC-131 or BG9588, both
humanised anti-CD40L antibodies. The first one failed in a
phase II double-blind trial due to inefficacy over placebo
[100]. The second one was associated with unacceptably high
rate of thromboembolic events [101].
Abatacept is a fusion protein comprised of Fc portion of
human IgG1 associated with a cytotoxic T lymphocyte anti-
gen (CTLA4). It is a selective co-stimulation modulator as it
inhibits the co-stimulation of T cells. A phase II trial of
abatacept in non-renal SLE patients failed to meet its primary
endpoint of reduction in new flares. A phase III trial of
abatacept in proliferative lupus nephritis (classes III and IV)
failed to meet its study endpoint of complete renal response
[102]. However, a very strict endpoint definition of complete
renal response was used in this study [102].
Considering the possible errors in the definitions of the
outcomes, a re-analysis of the same study data was undertaken
using outcome measures from the LUNAR and ALMS trials
and did show a positive outcome in favour of abatacept ther-
apy [103].
Other T cell targeting therapies are at a preliminary stage of
development in the treatment of SLE. Tyrosine kinases play a
central role in the signalling processes involved in the patho-
genesis of autoimmune disease [104]. Spleen tyrosine kinase
(Syk) is a cytoplasmic protein that is widely expressed in
many cells of the immune system including B and T cells.
Fostamatinib (R788), a Syk inhibitor has been studied in
lupus-prone mice and it significantly prolonged survival
delaying the onset of proteinuria and reducing kidney infil-
trates. R788 has been studied in patients with rheumatoid
arthritis (RA), but there have been no trials in SLE [104].
Other tyrosine kinase inhibitors including the JAK inhibitor,
tofacitinib, which has been approved for RA, and baracitinib
studied in RA, have not as yet been evaluated in SLE.
Several other T cell-targeting therapies at early stages of
development in SLE include the immunomodulatory mole-
cules such as the quinoline-3-carboxamide derivatives
(laquinimod and paquinimod), U1 small ribonucleotide frag-
ments (forigerimod) and sphingosine-1-phosphatase ana-
logues (fingolimod and KRP-203). Laquinimod, developed
for the treatment of multiple sclerosis, seems to decrease the
activation of T cells via toll-like receptor 4, contributing to an
anti-inflammatory effect. Two phase II randomised trials of
laquinimod have been completed in lupus arthritis and lupus
nephritis. Forigerimod (Lupuzor), which is a tolerogenic pep-
tide, has been studied in a phase II trial encompassed 149 SLE
patients showing some clinical benefit. It was well tolerated
and efficacious with regard to SRI [105].
Anti-interleukin-6 Therapies
IL-6 levels are found to be raised in the serum of SLE patients
and it has both pro-inflammatory and anti-inflammatory
effects.
Tocilizumab is a humanised monoclonal antibody targeted
against the IL-6 receptor. A phase I trial of this biological
treatment showed good tolerance to the drug with reduction
in active urinary sediment and autoantibody titres [106]. In the
study of Shirota et al., tocilizumab was used in 15 SLE pa-
tients with mild-moderate disease activity with a reduction in
the activity of T cells and B cells [107]. Nonetheless, concerns
were raised about its safety. There were dosage-related de-
creases in the absolute neutrophil count and clinically relevant
infections; therefore, further studies are needed to define the
role of tocilizumab in the SLE management.
Sirukumab is another monoclonal antibody against IL-6.
Both safety and pharmacokinetics were evaluated in a phase
I, double-blind, placebo-controlled study in patients with cu-
taneous or systemic lupus with mild, stable, active disease.
The study demonstrated good tolerability of sirukumab, al-
though it was associated with dose-independent reduction in
white cell, absolute neutrophil and platelet counts [108]. A
phase II randomised trial of CNTO 136 in patients with active
lupus nephritis is completed and the results are awaited.
Anti-tumour Necrosis Factor Therapies
The role of tumour necrosis factor (TNF)-α in SLE is contro-
versial [109]. In different strains of lupus mice, the expression
of TNF-α is often variable, and beneficial effects on the dis-
ease can be observed either after administration of TNF or
upon blockade. In kidney inflammation, the renal expression
of TNF is usually increased. In lupus mice, skin disease may
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be TNF-dependent, and anti-TNF treatment can cause wors-
ening of nephritis. In humans with SLE, some studies have
found relatively low concentrations of serum TNF-α, whilst
other studies have observed elevated amounts or no signifi-
cant differences between SLE patients and healthy controls. It
is important to bear in mind that there is a balance between
TNF and its soluble inhibitors (reviewed in [110]).
As it has been reported previously, the TNF blockers that
have been successful in the management of RA, Crohn’s dis-
ease and psoriasis are known to induce autoantibodies and
lupus-like syndromes. Therefore, their use in SLE is unclear
and they are mainly reserved for cases where arthritis is a
major feature. In small studies in SLE, anti-TNF therapy has
been associated with improvement in polyarthritis, and ne-
phritis [111, 112], but also with severe infusion reaction.
Anti-interferon-α Therapies
Numerous studies have demonstrated the role of IFN-α in the
pathogenesis of SLE. Murine studies with the New Zealand
Black mouse model of SLE showed that genetic deficiency of
the type I IFN receptor led to significantly reduced disease
activity [113]. Moreover, serum interferon-α levels have been
shown to correlate with disease activity and severity in SLE
patients. Gene expression microarray profiles demonstrate up-
regulation of interferon-inducible genes [114], particularly in
those with severe SLE manifestations such as lupus nephritis
and neuropsychiatric disease. Sifalimumab is a fully human
anti-interferon-α monoclonal antibody which was shown in a
phase I study to induce a dose-dependent inhibition of type I
interferon-induced mRNAs in patients with moderately active
SLE. A phase IIb trial evaluating the efficacy and safety of
sifalimumab in SLE achieved its primary endpoints using the
SRI(4) and the more stringent SRI (6–8) [115].
Anifrolumab, which is an anti-interferon-α receptor 1 an-
tibody, seemed to have more significant and sustained impact
on the interferon gene signature than sifalimumab, taking into
account the results of two phase II randomised open-label
studies. A recent report of a phase IIb study showed that
anifrolumab reduced disease activity more than placebo, par-
ticularly in patients with high interferon signature [116].
Therefore, anifrolumab has been selected for phase III studies.
Vaccination against IFN-α using IFN-α kinoid is another
therapeutic approach that has been investigated in murine
studies. The IFN-α immunogen induced transient neutralising
antibodies to the cytokine without apparent side effects, and
the lupus manifestations were delayed or prevented in kinoid-
vaccinated mice. These studies suggest a new therapeutic
strategy for the treatment of SLE [117].
Finally, rontalizumab [118], a recombinant humanised
monoclonal antibody, was evaluated in a phase II randomised,
double-blind, placebo-controlled study (ROSE) but it did not
meet the primary endpoint of significant improvement and
was withdrawn for further development [119].
Overall, treating refractory SLE patients is challenging be-
cause we need to deal with a tremendously heterogeneous
disease. It is a reality that biologic therapies are mainly used
in clinical scenarios where SLE patients remain resistant to
conventional immunosuppressive agents, although it would
be highly unlikely that one biologic agent will successfully
treat all the disease manifestations, in all patients. Clinicians
must beware of the importance of considering each patient as
a unique case.
Why Have Clinical Trials of Biologics in SLE so
Often Been Disappointing?
The previous section shows that many biologic agents have
not fulfilled their promise in large clinical trials. Rituximab
seemed beneficial in open studies [120], epratuzumab [96]
gave very promising results in a phase II trial and both
abatacept and rontalizumab had good biological reasons to
suggest efficacy. Yet all failed to reach the primary endpoint
in phase III studies. A number of possible reasons have been
proposed to explain this apparent discrepancy and include the
following:
1) Choice of endpoints—Since SLE is a very complex con-
dition, with potential manifestations in different organs,
the concept of response to therapy is more complicated
than in rheumatoid arthritis. Most trials have used one of
the validated measures of disease activity such as the
Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) or British Isles Lupus Assessment Group
(BILAG) 2004 index. The indices can be used to derive
numerical scores for activity or to define what constitutes
a flare of disease. No single index is perfect; all have
advantages and disadvantages. The best way to approach
this seems to be to design a composite index, incorporat-
ing BILAG, SLEDAI and a physician global score. One
advantage may be to reduce the apparent responder rate in
the ‘placebo’ group. This was done successfully in the
belimumab trials [76, 94] using an index where improve-
ment in SLEDAI was the key feature, and less success-
fully in the epratuzumab trials [96, 97] using an index in
which improvement in BILAG was key.
For renal trials, endpoints commonly describe total or par-
tial remission on the basis of measurements such as serum
creatinine or urine protein [92]. Where these definitions are
very strict, it may make it difficult to recognise truly important
clinical improvements. This was exemplified by the differing
results when the data from an abatacept trial was analysed in
two different ways [103].
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2) Selection of patients—Many studies exclude patients with
active neuropsychiatric or renal disease [76, 92, 94]. This
is a problem because these are exactly the types of pa-
tients most likely to be refractory to current standard-of-
care drugs. Onemight argue that the best chance of seeing
improvements lies in treating patients with the most se-
vere forms of disease.
3) Treatment of the ‘placebo’ group—For ethical reasons, it
would not be possible to treat the non-biologic group with
placebo alone. Thus, these comparator groups are typical-
ly treated with corticosteroids (often in appreciable doses)
and immunosuppressants [91, 92]. Since recruitment to
trials often rests heavily upon patients with skin and joint
activity (which are the most common forms of active
lupus, especially when renal and neuropsychiatric activity
is excluded from the trial), this level of treatment in the
comparator group often leads to a response rate of 40% or
higher, meaning that it is very difficult to prove any ad-
vantage of the treatment group statistically.
4) Requirement for large numbers of patients—It is striking
that the BLISS-52 [76] and BLISS-76 [94] belimumab
trials, which were almost the only ones to meet their pri-
mary endpoint, were also the largest with over 800 pa-
tients each. Since SLE is a rare disease, and since many
patients respond very well to standard therapy, it is often
hard to recruit patients into trials and this problem led to
discontinuation of RITUXILUP. Thus, the necessity for
finding hundreds of patients over many centres can add to
the complexity of such trials and can reduce chances of
success.
Other Clinical Research Challenges in SLE
In this review, we have concentrated on cardiovascular dis-
ease, fatigue and development of new therapies as key unmet
challenges in patients with SLE. There are other challenges
being addressed by researchers in the field.
Development of new biomarkers is important in order to
follow the course of the disease and make sure that activity is
treated appropriately. For example, neuropsychiatric symp-
toms occur in a large proportion of patients with SLE, but
are usually not due to active disease and do not require in-
creased immunosuppression [121]. Although a variety of dif-
ferent serological and imaging tests have been suggested as
aids to diagnosing which patients have true neuropsychiatric
SLE, none has achieved sufficient specificity or sensitivity to
be adopted into clinical practice (reviewed by Clark et al.
[122]). Equally, no serum or urine biomarkers are sufficiently
accurate in the diagnosis of incipient or relapsing lupus ne-
phritis that renal biopsies can be replaced.
Management of pregnancy in SLE is another developing
field. A large American study showed that 19% of 385 pa-
tients with inactive or stable SLE suffered adverse pregnancy
outcomes and risk factors increasing the chance of such out-
comes included positive lupus anti-coagulant, higher disease
activity and anti-hypertensive use [123].
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